MX420864B - Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante. - Google Patents

Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante.

Info

Publication number
MX420864B
MX420864B MX2019012911A MX2019012911A MX420864B MX 420864 B MX420864 B MX 420864B MX 2019012911 A MX2019012911 A MX 2019012911A MX 2019012911 A MX2019012911 A MX 2019012911A MX 420864 B MX420864 B MX 420864B
Authority
MX
Mexico
Prior art keywords
cells
transplantation
alloespecific
large scale
phenotype
Prior art date
Application number
MX2019012911A
Other languages
English (en)
Other versions
MX2019012911A (es
Inventor
Hernández Arimelek Cortés
Salazar Evelyn Katy Alvarez
Gómez Josefina Alberú
MELGAREJO María Gloria SOLDEVILA
Original Assignee
Univ Mexico Nac Autonoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mexico Nac Autonoma filed Critical Univ Mexico Nac Autonoma
Priority to MX2019012911A priority Critical patent/MX420864B/es
Priority to US17/085,284 priority patent/US20210130778A1/en
Publication of MX2019012911A publication Critical patent/MX2019012911A/es
Priority to US18/439,208 priority patent/US20240182853A1/en
Publication of MX420864B publication Critical patent/MX420864B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una metodología para obtener grandes números de células T reguladoras inducidas humanas in vitro específicas al antígeno del donante, con fenotipo y función supresora estable en presencia de citocinas proinflamatorias, mediante co-cultivos de células dendríticas derivadas de monocitos con células T ¿naïve¿, ambas provenientes de individuos no relacionados genéticamente (donante y receptor). Las células obtenidas con el presente método son del fenotipo CD4, CD25, CTLA-4 y FOXP3+ y presentan una función supresora específica de linfocitos T específicos para el antígeno del donante. Estas células mantienen su fenotipo y función supresora estable en presencia de las citocinas proinflamatorias TNF-¿ e lL-6. La estabilidad y el número obtenido las hace candidatas como herramientas terapéuticas para el trasplante.
MX2019012911A 2019-10-30 2019-10-30 Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante. MX420864B (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MX2019012911A MX420864B (es) 2019-10-30 2019-10-30 Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante.
US17/085,284 US20210130778A1 (en) 2019-10-30 2020-10-30 Method for large-scale production of human allospecific induced-regulatory t cells with functional stability in the presence of pro-inflammatory cytokines with therapeutic potential in transplantation
US18/439,208 US20240182853A1 (en) 2019-10-30 2024-02-12 Method for large-scale production of human allospecific induced-regulatory t cells with functional stability in the presence of pro-inflammatory cytokines with therapeutic potential in transplantation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019012911A MX420864B (es) 2019-10-30 2019-10-30 Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante.

Publications (2)

Publication Number Publication Date
MX2019012911A MX2019012911A (es) 2021-05-03
MX420864B true MX420864B (es) 2025-02-10

Family

ID=75686271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012911A MX420864B (es) 2019-10-30 2019-10-30 Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante.

Country Status (2)

Country Link
US (2) US20210130778A1 (es)
MX (1) MX420864B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120027674A1 (en) * 2010-07-27 2012-02-02 Baylor Research Institute Il-18 receptor as a novel target of regulatory t cells in cancer
US20140294792A1 (en) * 2013-02-22 2014-10-02 The Board Of Trustees Of The University Of Illinois T-REG Cell Expansion
US20170216354A1 (en) * 2015-06-12 2017-08-03 Batu Biologics, Inc. Clinically useful non-antigen pulsed dendritic cells
WO2018106885A1 (en) * 2016-12-07 2018-06-14 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CA3051469A1 (en) * 2017-01-27 2018-08-02 Abraham J And Phyllis Katz Cord Blood Foundation T cells derived from umbilical cord blood

Also Published As

Publication number Publication date
US20210130778A1 (en) 2021-05-06
US20240182853A1 (en) 2024-06-06
MX2019012911A (es) 2021-05-03

Similar Documents

Publication Publication Date Title
MX2018005207A (es) Expansion de celulas t gamma-delta residentes en tejido no hematopoyetico y usos de estas celulas.
MX2014002771A (es) Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades.
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
CO2018011804A2 (es) Receptores quiméricos de flt3 y métodos de uso de los mismos
AR107278A1 (es) Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos
MX2016016251A (es) Expansion de linfocitos con composicion de citocinas para inmunoterapia celular activa.
MX2021005480A (es) Metodos para aislar y expandir celulas.
MX2013010793A (es) Metodo y composiciones para inmunoterapia celular.
MX2022005389A (es) Terapia de celulas t con receptor de antigeno quimerico.
MX382541B (es) Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva.
EA202092243A1 (ru) Способы усиления персистенции адоптивно инфузированных т-клеток
MA40132A1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
CO2021000660A2 (es) Receptores químericos de steap1 y métodos de uso de los mismos
MX2019000022A (es) Células veto generadas a partir de linfocitos t de memoria.
MX2021005481A (es) Metodos para aislar y expandir celulas.
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
Shang et al. Nonclassical MHC Ib-restricted CD8+ T cells recognize Mycobacterium tuberculosis-derived protein antigens and contribute to protection against infection
CY1120220T1 (el) Μεθοδοι και κυτια για προσδιορισμο της καταστασης λοιμωξης απο φυματιωση
CL2023001433A1 (es) Muteína de il-2; proteína de fusión; ácido nucleico; vector; célula hospedera; métodos; uso
Ticha et al. TNFR2 expression is a hallmark of human memory B cells with suppressive function
MX2022003417A (es) Proteínas de fusión de il-10/fc útiles como mejoradoras de inmunoterapias.
MX420864B (es) Método para la obtención a gran escala de células t reguladoras inducidas aloespecíficas humanas y estables en presencia de citocinas proinflamatorias con potencial terapéutico en trasplante.
MX2021013005A (es) Metodos de fabricacion de celulas car-t alogenicas.
EA202192893A1 (ru) Среда для культивирования эукариотических клеток
AR085208A1 (es) Composiciones y metodos para alterar enfermedades autoinmunes